Shots:
- Eli Lilly has entered into a definitive agreement to acquire Ajax Therapeutics, incl. its lead asset AJ1-11095, strengthening Lilly’s capabilities in blood cancers
- As per the deal, Lilly will acquire Ajax for ~$2.3B in cash, inclusive of an upfront payment & subsequent clinical & regulatory milestone payments
- AJ1-11095 (PO, QD), a Type II JAK2 inhibitor, is being assessed in a P-I (AJX-101) trial for the treatment of pts with myelofibrosis, who received Type I JAK2 therapy, with dose selection expected in 2026
Ref: PRnewswire | Image: Ajax Therapeutics | Press Release
Related News: Eli Lilly to Acquire CrossBridge Bio for ~$300M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
